Zeaxanthin Boosts Cancer Immunotherapy, Chicago Study
Why it matters: Human trials slated for 2027 will test zeaxanthin supplementation in cancer patients receiving immunotherapy.
- Zeaxanthin strengthens CD8+ T‑cell receptor signaling, boosting tumor‑killing activity (University of Chicago study).
- Jing Chen’s team showed zeaxanthin combined with checkpoint inhibitors slowed tumor growth in mice and enhanced engineered human T‑cell killing.
- Human trials are slated for 2027 to evaluate zeaxanthin as a safe, widely available supplement for cancer immunotherapy patients.
University of Chicago researchers discovered that zeaxanthin, a carotenoid known for eye health, directly enhances CD8+ T‑cell activity and amplifies the effects of checkpoint inhibitor immunotherapy. In mouse models and lab tests on engineered human T cells, the nutrient slowed tumor growth and boosted cancer‑killing potency, prompting plans for human trials.
